NewLink Genetics Corporation Top Infectious Disease Scientist to Present at Special Zika Conference Called by American Society for Microbiology

AMES, Iowa, June 01, 2016 (GLOBE NEWSWIRE) — NewLink Genetics Corporation (NASDAQ:NLNK) today announced that Thomas P. Monath M.D., Chief Science Officer and Chief Operating Officer for the Infectious Disease Division of NewLink Genetics, will present at a scientific conference focused on the Zika virus hosted by the American Society for Microbiology (ASM) in collaboration with the American Society for Virology (ASV).

The conference, which is called, “What Does the Biology of Flaviviruses Tell Us About Zika: The Importance of Fundamental Virus Biology,” is being held in Washington, D.C., on June 1.

NewLink Genetics’ Infectious Disease Division, which is based in Devens, Mass., is focused on finding innovative and life-saving treatments for people who have no or few options available to them, including Ebola and Zika virus diseases. The World Health Organization (WHO) has declared the Zika virus to be an international public health emergency due to its role in transplacental infection and birth defects in newborns, including microcephaly.

Dr. Monath, an internationally-recognized expert on flaviviruses – a family of more than 70 viruses that includes West Nile, dengue, yellow fever and Zika – will deliver a presentation entitled, “Cognate Pathogenesis of Neurotropic Flaviviruses Relevance to Vaccine Development.” Dr. Monath has published widely on this group of viruses, including several books, and has led development of new vaccines against flaviviruses including dengue, West Nile, Japanese encephalitis and yellow fever. His presentation at the ASM conference will focus on the common themes in pathogenesis and vaccine development between Zika virus and other members of the flavivirus group.

“NewLink Genetics is committed to developing a vaccine solution to the unfolding human tragedy caused by Zika virus,” said Dr. Monath. “Our R&D group has decades of experience in developing successful vaccines against closely-related flaviviruses, which we are leveraging to accelerate our Zika vaccine program.”

“ASM has acted quickly to bring together academia, industry and public policy leaders to lead the call for immediate and aggressive action against Zika virus, and we are pleased Tom is part of this important conference,” said Charles J. Link, M.D., CEO and Chief Scientific Officer of NewLink Genetics. “Our team gained considerable experience during the Ebola crisis collaborating with national and international partners in a rapidly evolving public health environment, and we look forward to similar collaborative efforts on Zika.”

About the Zika Virus

The Zika virus is a mosquito-borne flavivirus related to dengue, yellow fever and West Nile virus. The World Health Organization has declared the Zika virus an international public health emergency and there is no current vaccine and no course of treatment for the Zika virus.

About NewLink Genetics Corporation

NewLink Genetics is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink Genetics’ portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink Genetics’ product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “potential,” “will,” “could,” “should,” “seek” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include any statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in “Risk Factors” and elsewhere in NewLink Genetics’ Annual Report on Form 10-K for the year ended December 31, 2015 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink’ Genetics’ views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics’ views as of any date subsequent to the date of this press release.

CONTACT: Corporate Contact:
Jack Henneman
Chief Financial Officer
(515) 598-2561

Investor Contact:
Donna LaVoie
617-374-8800, ext. 107

David Connolly 
617-374-8800, ext. 108